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Abstract
Resistant hypertension (RH) is a clinical condition in which the hypertensive patient has 
become resistant to drug therapy and is often associated with increased cardiovascular 
morbidity and mortality. Several signaling pathways have been studied and related to 
the development and progression of RH: modulation of sympathetic activity by leptin 
and aldosterone, primary aldosteronism, arterial stiffness, endothelial dysfunction, and 
variations in the renin-angiotensin-aldosterone system (RAAS).
Keywords: resistant hypertension, signaling pathways, blood pressure, drug resistance
1. Introduction
Systemic arterial hypertension (SAH) stands out as the major independent risk factor related 
to cardiovascular disease (CVD) and remains the greatest modifiable risk factor, despite 
the important advance in the knowledge of its pathophysiology and availability of effec-
tive methods for its treatment. There are approximately 13.3 billion people with SAH in the 
world, and in developed Western countries, better controls are obtained on blood pressure 
(BP) levels.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Resistant hypertension (HAR) affects on average 30% of the adult population, about 1.2 bil-
lion individuals worldwide. Although the exact prevalence of HAR is still not established, it 
is estimated that this condition reaches 12–15% of hypertensive individuals.
2. Resistant hypertension
Resistant hypertension (RH) is characterized by a condition in which the patient requires 
four or more antihypertensive medications, including a diuretic, regardless of blood pressure 
control. RH patients can be classified as controlled or uncontrolled according to the achieve-
ment of the blood pressure goals [1].
The RH affects approximately 13–25% of the hypertensive population [2–4] and represents 
a risk factor for cardiovascular events. Results from the antihypertensive and lipid-lowering 
treatment to prevent heart attack trial (ALLHAT) showed increased hazard ratios for stroke 
(1.57), end-stage renal disease (1.95), heart failure (1.88), coronary heart disease (1.44), and 
all-cause mortality (1.30) in RH compared to nonresistant hypertensive subjects [5].
RH is a multifactorial condition, and several environmental and genetic factors contribute to 
the development and progression of the disease. Firstly, the identification of pseudoresistance 
must be performed to identify true resistant hypertensive patients, caused mainly due to poor 
BP measurements, lack of adherence, suboptimal therapy, and white coat hypertension. In 
addition, secondary causes of RH, such as primary aldosteronism, pheochromocytoma, renal 
artery stenosis, or Cushing’s syndrome should be identified since the pharmacological treat-
ment will be specific for each condition. Among the factors associated with an increased risk 
for RH are: older age, African origin, female gender, overweight, and obesity [1, 6].
The RH presents three relevant characteristics: (1) high incidence of the following comorbidi-
ties: obstructive sleep apnea [7], thyroid disorders [7], primary aldosteronism [8, 9], reduced 
plasmatic renin activity, obesity [6], diabetes mellitus [1, 6]; (2) high prevalence of target organ 
damage; and (3) high blood pressure (BP) levels measured by ambulatory blood pressure 
monitoring (ABPM) [10–12].
The achievement of the BP goals relies on physician examination and on patient characteristics and 
compliance to pharmacological and nonpharmacological treatments. It is well know that obesity, 
excessive alcohol and/or salt intake, sedentary lifestyle, smoking, insulin resistance, difficulty in 
adopting dietary measures, and lack of adherence to therapeutic treatment affects BP control [12]. 
In addition, prescription of high-cost medicines by physicians, multiple administration regimens, 
suboptimal doses, and presence of adverse effects are associated with uncontrolled BP [13].
The factors associated with diagnostic and treatment of RH include lifestyle, detailed history 
of medication adherence, correct BP measurement, biochemical analysis for dosage of electro-
lytes, glucose, and creatinine, as well as determination of protein and sodium in the urine [12].
The exclusion of pseudohypertension is also necessary. For example, Mönckeberg’s sclerosis 
is a condition characterized by the loss of elasticity and thickening of the walls of the muscular 
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Table 1. Forms of secondary hypertension associated with RH (modified from Vongpatanasin [14]).
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arteries caused by a calcification of the tunica media constituted of smooth muscle. In the 
measurement of blood pressure by noninvasive methods, the patient presents high BP values, 
while in reality, the pressure is normal; therefore, it is necessary to use invasive measurement 
methods to correctly measure the BP [12]. In white coat hypertension, also a condition of pseu-
doresistance, the patient exhibits high values during the verification in the physician’s office. 
It can be excluded by 24-h ABPM. It is estimated that 30% of patients with elevated BP and 
with treatment of up to three drugs present this condition of white coat hypertension [12, 14].
In order to complete the diagnosis of RH, there are some clinical situations that are considered 
as secondary causes of this condition, such as: primary hyperaldosteronism, pheochromocy-
toma, fibromuscular dysplasia, patients with increased risk of atherogenesis [12], obstructive 
sleep apnea, renal artery stenosis, renal parenchymal disease, Cushing’s syndrome, and thyroid 
and parathyroid diseases [10]. These forms of secondary hypertension present high prevalence 
in association with RH, as can be verified in Table 1. Hyperaldosteronism results from the 
excessive production of aldosterone, a hormone that is produced in the adrenal glands and 
that decreases the excretion of sodium and increases the excretion of potassium by the kid-
neys, sweating, and saliva. The determination of the rate of aldosterone/renin ratio is used as 
screening tool for hyperaldosteronism diagnostic, and if any alteration is confirmed, diagnostic 
Figure 1. Recommendations for diagnosis of RH. Modified from Calhoun et al. [1] and Passarelli et al. [16]. Abbreviation: 
WCH, white coat hypertension.
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imaging and blood samples from each side of the adrenal glands are used to corroborate the 
diagnosis [12]. Obstructive sleep apnea consists of the collapsing of the pharynx walls hamper-
ing the adequate respiration of the individual. The patient is then submitted to a nocturnal poly-
somnography in order to monitor respiration and body functions during sleep for diagnosing 
the condition [15]. For more information on diagnostic and treatment methods, see Table 1 [14].
A flowchart (Figure 1) summarizes the steps involved in the diagnosis of RH according to the 
American Heart Association Statement [1, 16].
Although RH is a multifactorial condition, excess sodium, fluid retention, increased activation of 
the renin-angiotensin-aldosterone system, and higher sympathetic tone are among the most well-
described mechanisms of BP elevation in RH. The complex pathophysiology of the development 
and progression of RH requires further investigation to identify molecular mechanisms that could 
be translated into diagnostic and more assertive therapeutic strategies. In the following sessions, 
the signaling pathways and the participation of miRNA in their regulation will be discussed.
3. Renin-angiotensin-aldosterone system
The renin-angiotensin-aldosterone system (RAAS) is responsible for the hemodynamic equi-
librium. This is possible due to the effects of this system on the kidneys, which act in the 
sodium water balance, and also due to the influence in the vascular resistance on the peripheral 
blood vessels, thus permitting the maintenance of the BP [17]. In order to the RAAS to produce 
a response, it is necessary for some type of alteration to occur in the circulating blood volume, 
such as blood loss, dehydration, or even pumping failure by the ventricles [18] (Figure 2).
Juxtaglomerular apparatus comprises afferent arterioles in the distal part of the ascending 
branch of the loop of Henle in the renal glomeruli. The cells that line these arterioles in the region 
of the apparatus are called juxtaglomerular cells and are able to recognize the BP inside these 
vessels [18]. Moreover, the cells that line the loop of Henle in the region of the juxtaglomerular 
Figure 2. Hemodynamic control of RAAS. Modified from Maron and Leopold [18]. Abbreviation: ACE, angiotensin 
converting enzyme.
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apparatus are called macula densa and respond to changes in the sodium concentration of the 
filtrate. By detecting these changes, the cells of the dense macula stimulate juxtaglomerular cells 
to produce an enzyme called renin that is released into the bloodstream. This enzyme is respon-
sible for the production of angiotensin I (AngI) through the cleavage of angiotensinogen, which 
is synthesized and secreted by the liver. In the pulmonary and renal endothelium, an enzyme 
called angiotensin-converting enzyme (ACE), which hydrolyzes the circulating AngI in angio-
tensin II (AngII), is present. The angiotensin 1 receptor (AT1) is activated by AngII, thus promot-
ing a vasoconstrictive response in the blood vessels, in addition to stimulating the adrenal gland 
to produce aldosterone. The renal tubules respond to the aldosterone by retention of sodium 
and water, which will promote increased blood volume and consequently, BP elevation [19, 20].
The RAAS constitutes the main signaling pathway involved in the long-term control of the 
BP. Innumerous regulators participate in this biochemical cascade of communication such as 
renin, angiotensinogen, AngI and II, ACE 1 and 2, and aldosterone and angiotensin- (1-7) [Ang-
(1-7)]. The deregulation of one or more effectors of this system contributes to failures in blood 
pressure control, usually leading to hypertension [21]. Resistant hypertension is accompanied 
by intravascular fluid retention that can be attributed, at least in part, to dysregulation in the 
renin-angiotensin-aldosterone system. Previous studies have found evidence of intravascular 
volume expansion (higher levels of brain-type natriuretic peptide—BNP and atrial natriuretic 
peptide—ANP) and aldosterone excess (higher levels of plasma and urinary aldosterone, aldo-
sterone to renin ratio) in resistant hypertension compared to controls [22]. Similarly, another 
study reported higher volume of fluid by thoracic electrical bioimpedance, suggesting that the 
intensification of diuretic therapy in those patients could be beneficial [23]. ANP and BNP are 
hormones that regulate cardiovascular hemodynamics. They are secreted by cardiac atria and 
cardiac ventricles, respectively, in response to stretch or pressure. Natriuretic effects are medi-
ated by subtype A-natriuretic peptide receptor, which is expressed in several tissues, includ-
ing kidneys, blood vessels, adrenal glands, and adipose tissue. ANP produces its natriuretic 
actions by increasing glomerular filtration rate and inhibits sodium transport in proximal 
tubule and inhibition of aldosterone release in adrenal cells. The latter effect is also attributed 
to BNP [24]. Aldosterone is one of the most studied RAAS components in RH; several studies 
had shown that aldosterone excess is a common characteristic of RH. In addition, primary 
aldosteronism is the most common secondary cause in the patients with RH [8]. This condition 
is characterized by excessive autonomic secretion of aldosterone by the adrenal gland, being 
the production of adenomas and idiopathic hyperaldosteronism in the main forms [25, 26]. 
This secretion, stimulated by renin, promotes the retention of sodium and water, promoting 
the elevation of blood volume, and consequently the increase of BP. When it is released into the 
bloodstream, the aldosterone diffuses through the membrane into the cytosol of renal tubular 
epithelial cells, subsequently binding to a family of NRC2-type mineralocorticoid receptors. 
This aldosterone-receptor complex will be translocated to the nucleus, activating the synthesis 
of proteins related to sodium and potassium transport, such as Na+ K+ ATPase (Figure 3) [27].
An important signaling pathway in the primary aldosteronism is the phosphoinositide 
3-kinase (PI3K) pathway with the activation of mammalian target of rapamycin (mTOR), 
when overactivation is involved in the tumorigenesis and metastasis in some types of human 
tumors such as renal cancer, adrenal carcinoma, and pheochromocytoma [28–30] (Figure 4) 
[29]. The PI3K/AKT/mTOR pathway is regulated in response to the signaling of growth fac-
tors such as the epidermal growth factor (EGF) through receptor tyrosine kinases (RTKs) [31].
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Figure 3. Signaling pathway of Na+/K+-ATPase activity and aldosterone.
Figure 4. Signaling pathway involved in primary aldosteronism. Abbreviations: AKT, protein kinase B; EGFR, EGF 
receptor; ERK, extracellular regulated kinase; GPCR, G-protein coupled receptor; HB-EGF, heparin binding EGF; 
MAPK, mitogen-activated protein kinase; PIP2, phosphatidylinositol 4,5-biphosphate; PIP3, phosphatidylinositol 
(3,4,5)-triphosphate; PKC, protein kinase C; PLD, phospholipase; S1P, sphingosine-1-phosphate.
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Another stimulus to the release of aldosterone is the action of sphingosine-1-phosphate (S1P) 
by means of the activation of the PI3K/AKT (protein kinase B) and mitogen-activated protein 
kinase (MEK)/extracellular regulated kinase (ERK) pathway in glomerular cells of the adrenal 
glands (Figure 4) [30]. S1P is a bioactive sphingolipid intracellularly formed that acts as a 
second messenger mediating regulatory processes such as cell differentiation, migration and 
contraction, modulation of immune response, and angiogenesis, and this molecule is consid-
ered to be the key hormone for hemodynamic stability in humans [32, 33]. Its action involves 
the activation of phospholipase D (PLD), calcium influx (Ca2+) from the extracellular medium 
and phosphorylation of α and β isoforms of protein kinase C (PKC) [25, 26, 32].
Previous studies had shown excess of aldosterone in uncontrolled RH compared to controlled 
group. The same study demonstrated that aldosterone was correlated to arterial stiffness 
[34]. Furthermore, higher aldosterone levels were associated with the T allele for the poly-
morphism-344 C/T CYP11B2 (aldosterone synthase gene) in RH subjects, and this effect was 
shown to be more pronounced in patients under spironolactone treatment [35]. Studies have 
demonstrated significant reductions in blood pressure with addition of mineralocorticoid 
receptors antagonists, such as spironolactone, and that drug has been suggested as the opti-
mal fourth-line drug for BP control in RH.
Angio-(1-7) is a heptapeptide that carries out an important function in the RAAS. This mol-
ecule is formed both by the action of ACE 1 (dependent pathway) and the hydrolysis of 
AngII by the ACE 2 (independent pathway) [36, 37], being the last one in the most important 
pathway in the formation of Ang-(1-7) [38]. This molecule produces its AngII endogenous 
counter-regulatory effects on RAAS (vasodilation, cardio protection, natriuresis, and diuresis, 
angiogenesis inhibition, and cellular growth) [39] through the binding to its specific receptor 
called Mas, a G protein-coupled receptor [25, 40, 41].
The ACE2/Ang-(1-7)/Mas signaling pathway consists in one of the RAAS axes that opposes, in 
terms of function, to another classical axis of this system, the ACE/AngII/AT
1
R. The imbalance 
of these two opposing axes, mainly in the direction of the ACE/AngII/AT
1
R axis, predisposes 
to cardiovascular diseases and other disorders [37, 41].
The Ang-(1-7)/Mas complex regulates different signaling pathways, such as PI3K/AKT and 
ERK signal, and involves the maintenance of some effectors like nitric oxide (NO) [25, 41], 
FOXO1 (forkhead box 1) [39] and cyclooxygenase-2 (COX-2) [40] (Figure 5). Studies report that 
due to the participation of the Ang-(1-7) in these mechanisms, this heptapeptide is related to 
pathological conditions such as fibrosis and inflammatory processes in some organs, like lungs, 
liver, and kidneys [42]. Other findings demonstrate that Ang-(1-7), through the interaction with 
its Mas receptor, stimulates the activation of the nitric oxide synthesis (eNOS) in endothelial 
cells, promoting vasodilation [25, 36, 41].
Another study demonstrates that Ang-(1-7), through the interaction with its specific Mas 
receptor, promotes the increase in nitric oxide (NO) and prostaglandins (PG) synthesis and 
release, leading to vasodilation and inhibition of cellular growth, opposing to the vasocon-
strictor and proliferative effects mediated by the interaction of AngII with its AT
1
 receptors. 
The imbalance between these two axes of the RAAS, reflected by the imbalance between the-
ses peptides, which are observed in cardiovascular diseases, can lead to the decrease in NO 
and consequently to endothelial dysfunction (Figure 5) [43].
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3.1. Sympathetic nervous system
Sympathetic nervous system regulates cardiac output and peripheral vascular resistance (vaso-
constriction) through release of norepinephrine and epinephrine, resulting in increase in blood 
pressure. At the renal level, SNS activation increases renin release from juxtaglomerular cells 
and modulate tubular sodium reabsorption [44]. RH patients have reduced heart rate variabil-
ity, which is a marker for SNS activity. It was shown that 63% of the patients present a non-
dipping pattern (BP does not drop at night), which indicate sympathetic overflow. Moreover, 
sympathetic activation also increases sodium reabsorption and promotes renin secretion, and 
renal denervation has been investigated for the treatment of resistant hypertension. In spite first 
studies in humans had shown promising results, randomized and blinded clinical trials dem-
onstrated no benefit on BP control compared to sham procedure [45]. Another intervention that 
has been tested is baroreflex activation therapy. Carotid sinus stimulation reduces BP in patients 
with uncontrolled RH, showing the import role of sympathetic activity in this condition [46–48].
3.2. Adipokines
Adiponectin and leptin are two of the adipokines produced in adipose tissue. Obesity is an 
important comorbidity in RH, and plasma levels of adiponectin and leptin were reported to be 
lower and higher, respectively, in RH [34, 49]. Leptin is a peptide hormone that is expressed 
Figure 5. Signaling pathway of the SRAA axis. The figure shows the regulatory processes for the Ang-(1-7)/Mas in 
different signaling pathways, compared with the opposing RAAS classical axes of this system, the ACE/AngII/
ATR. Abbreviations: AKT, protein kinase B; DAG, diacylglycerol; IP3, inositol triphosphate; PG, prostaglandin; PIP2, 
phosphatidylinositol 4,5-biphosphate; PIP3, phosphatidylinositol (3,4,5)-triphosphate; PLC, phospholipase C.
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in a variety of tissues, such as lymphoid tissue, pituitary gland, skeletal muscle, placenta, and 
ovary [50]. However, white adipose tissue is the main responsible for the synthesis and secre-
tion of this peptide, which has effects to act on the hypothalamus in order to decrease appetite 
and stimulate sympathetic activity of the nervous system (Figure 6) [51]. Elevated levels of 
leptin stimulate neurons in the hypothalamus to secrete a precursor protein that is cleaved 
in α-melanocyte stimulating hormone, which binds to melanocortin 3 and melanocortin 4 
receptors. The binding of this peptide to the receptors stimulates the sympathetic nervous sys-
tem, elevates the energy expenditure, decreases food intake, and activates the hypothalamic-
pituitary-adrenal axis [52–54]. A mechanism that demonstrates which factors are involved in 
the generation of hypertension associated with obesity is represented below (Figure 6) [51].
3.3. Insulin resistance and hypertension: the role of the caveolin-1 (CAV1) gene
It was recently demonstrated that the gene caveolin-1 (CAV1), located in the chromosome 7q31.1 
[55], constitutes a gene that is associated with metabolic dysfunction in animal and cellular mod-
els, especially in insulin resistance, proving to be a potential marker for this condition in human 
beings [56]. Genetic variations in CAV1 are involved in the mechanism of insulin signaling and 
vascular function (Figure 7), shown in studies with animal models and cell culture [57, 58].
Increase in homeostasis model assessment of insulin resistance (HOMA-IR) shows that CAV1 is 
not only a genetic marker for dysfunction but also provides information about a potential 
mechanism of development of insulin resistance and hypertension in humans [56].
CAV1 is a regulatory gene for insulin signaling and insulin receptor stability [56]. Specifically, 
CAV1 binds directly to the insulin receptor in the adipocytes and the disturbance of this com-
plex by GM3 ganglioside causes alteration in insulin signaling [59] (Figure 7). In addition, the 
decrease in CAV1 activity results in a 90% reduction in insulin receptor levels in the adipo-
cytes of knockout rats [60].
Figure 6. Signaling leptin pathway. The figure outlines the relationship between leptin and mechanisms involved in 
the neurons signaling as it stimulates the SNS, processes involved in pathogenesis of hypertension linked to obesity. 
Modified from Rahmouni et al. [51]. Abbreviations: FFA, free fatty acids; RAS, renin-angiotensin system.
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Although the role of CAV1 in insulin-mediated glucose uptake is not well elucidated [60], 
this gene demonstrated relevance in the translocation of glucose transporter 4 (GLUT4) to 
adipocyte [61] and muscle cells [62].
3.4. Vascular stiffness and endothelial dysfunction
Previous studies have showed the participation of vascular stiffness and endothelial dysfunc-
tion in the pathogenesis of resistant hypertension. An increased carotid-femoral pulse wave 
velocity was observed in RH patients compared to non-RH hypertension, demonstrating the 
impairment of elasticity in these vessels. In addition, flow-mediated dilation was found to be 
reduced in RH, reflecting an endothelial dysfunction [63].
3.4.1. Epidermal growth factor receptor in the vascular smooth muscle
The activation of the signaling pathway of the epidermal growth factor receptor (EGFR) by 
matrix metalloproteinase (MMP), stimulated by G protein-coupled receptor (GPCR) agonists, 
such as catecholamines, endothelin-1 (ET-1) and AngII, leads to the increase of the oxida-
tive stress, and promotes stimulation of the hypertrophic growth and consequently increase 
in the muscular tone in hypertension (Figure 8) [64]. Among these receptors, adrenoceptors 
and angiotensin receptors can be mentioned that contribute to the hypertension pathogenesis 
mainly through the vasoconstrictor effects produced after stimulation [65, 66].
Figure 7. CAV1 signaling pathway. The stimulation of tyrosine kinase insulin receptor CAV1 signaling pathway leads to 
activation of PI3K resulting in translocation of the vesicle and exhibition of the GLUT4 in cell membrane. Abbreviations: 
AKT, Akt/protein kinase B; AS160, Akt substrate of 160 kDa; GLUT4, glucose transporter 4; GM3, ganglioside; IRS-1, 
insulin receptor substrate 1; PDK, phosphoinositide-dependent kinase-1; PIP2, phosphatidylinositol 4,5-biphosphate; 
PIP3, phosphatidylinositol (3,4,5)-triphosphate.
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The vasoconstrictor responses promoted by this pathway are mediated by phospholipase C 
(PLC), DAG, and Ca2+ besides the growth promotion pathway involving the tyrosine recep-
tor and mitogen-activated protein kinases (MAPKs) (Figure 9) [67]. Studies have shown a 
connection between the GPCR stimulus with the MAPK signaling pathway (through the 
dependent activation of MPM) in the vascular smooth muscle cells [65, 68–70]. Associations 
Figure 9. Signaling pathways involved in the development and progression of RH. The vasoconstrictor responses 
promoted by this pathway are mediated by phospholipase C (PLC), DAG, and Ca2+ besides the growth promotion 
pathway involving the tyrosine receptor and mitogen-activated protein kinases (MAPKs).
Figure 8. EGFR signaling pathway in vascular smooth muscle. The agonist action of the GPCRs stimulates NOX1 pathway 
and leads to the increase in the oxidative stress NOX1, which activates the signaling pathway of the EGFR. Abbreviations: 
AKT, protein kinase B; DAG, diacylglycerol; HB-EGF, heparin binding EGF; IP3, inositol triphosphate; NOX1, 
NADPH oxidase 1; PIP2, phosphatidylinositol 4,5-biphosphate; PIP3, phosphatidylinositol (3,4,5)-triphosphate; PLC, 
phospholipase C; ROS, reactive oxygen species.
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have been made between GPCR stimulus by MPM’s such as MPM-2, MPM-3, and MPM-7 in 
cardiomyocytes, fibroblasts, and epithelial and endothelial cells [71] with consequent devel-
opment of cardiovascular hypertrophy associated with hypertension [72–75] (Figure 9).
3.4.2. CYP4A (cytochrome P450-4A)/20-HETE (20-hydroxyeicosatetraenoic acid)
20-HETE is an arachidonic acid metabolite formed through reactions catalyzed by the cyto-
chrome P450-4A enzymatic complex (CYP4A) in vascular smooth muscle cells and is related 
to vascular dysfunction and arterial hypertension (Figure 10) [76]. This molecule has vaso-
constrictive action and exerts an important role in vascular function and in the development 
and progression of cardiovascular diseases [77]. Studies have demonstrated the relationship 
between genetic variations in precursors of 20-HETE formation and the elevation of this 
metabolite and the BP in humans [78, 79].
In Dahl SS (salt-sensitive) rats, a genetic model of salt-sensitive hypertension, 20-HETE has 
been shown to contribute to the increase in total peripheral resistance by reducing the ability 
of the vascular system to respond to direct vasodilation stimulation by reducing vascular 
function, thus contributing to an increase in BP [80, 81].
Some studies demonstrate that reactive oxygen species (ROS) are important molecules in the 
development of oxidative stress, playing an important role in vascular dysfunction in Dahl 
SS rats [82, 83]. The chronic exposure to low levels of AngII in these animals may lead to an 
increase in oxidative stress by elevating ROS cellular concentrations, thus contributing to the 
Figure 10. AngII stimulates signaling pathway through 20-HETE. The stimulation of GPCR by AngII agonist activates 
PLA2, which shoots the signaling intracellular pathway leading to activation of PKC as release calcium influx. 
Abbreviations: LO, lipoxygenase; LT, leukotriene; PGE2, PG E2; PLA2, phospholipase A2; PGH2, PG H2; PGI2, 
prostacyclin; ROS, reactive oxygen species; TXA2, thromboxane A2.
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reduction of vascular relaxation even when these animals are submitted to a sodium restric-
tion diet or are normotensive [84].
4. Concluding remarks and future directions
Due to the difficulty of studying RH in animal and in vitro models, the studies are clinical and 
poorly understood in terms of mechanisms. Thus, we decided to describe the microRNAs that 
interact with the most relevant pathways in RH. To date, several miRNAs have been identi-
fied and are related to the complications of resistant hypertension.
Epigenetic as well as genetic factors are identified every day and they are associated with 
variation in blood pressure levels. As reviewed herein, mutation polymorphism in some sig-
naling pathway gene may increase or decrease the expression of some microRNAs, which 
are involved both in RH development and therapy response as RH-associated complications 
such as renal failure, coronary artery disease, cardiac hypertrophy, stroke, and among oth-
ers. Therefore, the use of microRNA as biomarkers in prevention, diagnosis, and therapy of 
this disease may help to understand the disease, improve pharmacology therapy as well as 
prevent complications.
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